Home Newsfeeds Wolfe Research Upgrades Southern Copper to Peer Perform

Wolfe Research Upgrades Southern Copper to Peer Perform

Wolfe Research analyst Timna Tanners upgrades Southern Copper (NYSE:SCCO) from Underperform to Peer Perform.

byBenzinga Newsdesk

January 11, 2023

1 minute read

Wolfe Research analyst Timna Tanners upgrades Southern Copper (NYSE:SCCO) from Underperform to Peer Perform.

News

‘Nvidia’s Top A.I. Chips Are Selling For More Than $40,000 On eBay’ – CNBC

By Happy Mohamed

April 14, 12:59 PM

https://www.cnbc.com/2023/04/14/nvidias-h100-ai-chips-selling-for-more-than-40000-on-ebay.html Nvidia’s H100 graphics cards are selling for more than $40,000 on eBay. The high-end chips are still essential for

EBAY

Concrete Pumping Holdings Q1 EPS $0.11 Beats $0.05 Estimate, Sales $93.58M Miss $94.67M Estimate

By Michael Horton

March 9, 5:13 PM

Concrete Pumping Holdings (NASDAQ:BBCP) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.05 by 120 percent. This is a 1000 percent increase over earnings of $0.01 per share

BBCP

Biora Therapeutics Provides Guidance On Anticipated Milestones During 2024; Says We Begin 2024 In The Clinic With Our Phase 1 Study For BT-600, Which Will Be A Major De-Risking Step In The Development Of Our NaviCap Platform

By Benzinga Newsdesk

January 16, 9:02 AM

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided guidance on anticipated milestones during 2024. "In 2023, we completed the transformation of

BIOR

Morgan Stanley Maintains Equal-Weight on Palantir Technologies, Lowers Price Target to $10

By Benzinga Newsdesk

October 20, 8:35 AM

Morgan Stanley analyst Keith Weiss maintains Palantir Technologies (NYSE:PLTR) with a Equal-Weight and lowers the price target from $11 to $10.

PLTR

Wolfe Research Upgrades Southern Copper to Peer Perform

Related Posts

‘Nvidia’s Top A.I. Chips Are Selling For More Than $40,000 On eBay’ – CNBC

Concrete Pumping Holdings Q1 EPS $0.11 Beats $0.05 Estimate, Sales $93.58M Miss $94.67M Estimate

Biora Therapeutics Provides Guidance On Anticipated Milestones During 2024; Says We Begin 2024 In The Clinic With Our Phase 1 Study For BT-600, Which Will Be A Major De-Risking Step In The Development Of Our NaviCap Platform

Morgan Stanley Maintains Equal-Weight on Palantir Technologies, Lowers Price Target to $10